StreetInsider.com News Articles

AIAI Holdings signs LOI to acquire defense firm from affiliated entity

Thu, 03 Sep 2026 08:31:25 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) has signed a letter of intent to acquire a controlling interest in a defense industry business held by Messier 42 LLC, an affiliated entity of the company, according to a press release dated September 3, 2026.

The transaction is expected to close as early as the fourth quarter of 2026. Messier 42 LLC projects the acquired business will generate $250 million in free cash flow in the 12 months following the closing. The company said the deal is expected to be accretive to AIAI stockholders.

Because of the related-party nature of the transaction, AIAI is required to

AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company

Thu, 03 Sep 2026 08:30:00 -0400

With Projected $250M of Annual Free Cash Flow Post Closing

DALLAS, TX / ACCESS Newswire / September 3, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, announced that the Company has entered into a letter of intent with its affiliated entity, Messier 42 LLC ("M42"), to acquire a controlling interest in one of M42's businesses with operations in the defense industry.

M42 projects that this business is expected to produce $250 million in Free Cash Flow

AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company

Thu, 03 Sep 2026 08:30:00 -0400

With Projected $250M of Annual Free Cash Flow Post Closing

M42 projects that this business is expected to produce $250 million in Free Cash Flow

NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

Tue, 01 Sep 2026 07:00:00 -0400

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced today the appointment of Dr. Keith M. Fournier, PhD, RAC, to its Board of Directors.

Dr. Fournier is a highly experienced pharmaceutical executive with more than two decades of leadership across drug development, global regulatory strategy and cross-functional portfolio management. His career has spanned the development lifecycle from Investigational New Drug (IND) activities through global

NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

Tue, 01 Sep 2026 07:00:00 -0400

NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 07:00:00 -0400

Virtual corporate presentation available September 11, 2026
NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.